Last €54.18 EUR
Change Today -0.271 / -0.50%
Volume 2.8K
As of 12:44 PM 01/29/15 All times are local (Market data is delayed by at least 15 minutes).

merck & co. inc. (6MK) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/23/15 - €56.15
52 Week Low
01/30/14 - €38.18
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for MERCK & CO. INC. (6MK)

merck & co. inc. (6MK) Details

Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products worldwide. The company’s Pharmaceutical segment offers human health pharmaceutical products, such as therapeutic and preventive agents for the treatment of human disorders in the areas of cardiovascular, diabetes and obesity, respiratory, women's health and endocrine, inflammatory and infectious diseases, oncology, ophthalmology, immunology, infectious diseases, and others. This segment also provides vaccines, including preventive pediatric, adolescent, and adult vaccines. Its Animal Health segment discovers, develops, manufactures, and markets animal health products comprising vaccines, antibiotics, and anti-inflammatory drugs for respiratory diseases, as well as products for the treatment of fertility disorders. The company’s Consumer Care segment develops, manufactures, and sells over-the-counter products consisting of non-drowsy antihistamines; decongestant-free cold/flu medicine for people with high blood pressure; nasal decongestant sprays; and products for occasional constipation, frequent heartburn, and overactive bladder in women; foot care products, including topical antifungal, and foot and sneaker odor/wetness products; and sun care products, such as sun care lotions, sprays, and dry oils. The company serves drug wholesalers and retailers, hospitals, government agencies, physicians, physician distributors, veterinarians, animal producers, food chain and mass merchandiser outlets, club stores, and specialty channels, as well as managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions. It has collaborations with AstraZeneca LP, Pfizer Inc., Samsung Bioepis Co., Ltd., Sanofi Pasteur S.A., and Sysmex Inostics GmbH. The company was founded in 1891 and is headquartered in Whitehouse Station, New Jersey.

77,300 Employees
Last Reported Date: 02/27/14
Founded in 1891

merck & co. inc. (6MK) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $1.5M
Executive Vice President and President of Mer...
Total Annual Compensation: $1.2M
Executive Vice President and President of Glo...
Total Annual Compensation: $957.3K
Compensation as of Fiscal Year 2013.

merck & co. inc. (6MK) Key Developments

Merck & Co to Discontinue Commercialization of HCV Drug Victrelis in US

Merck & Co (US) has informed the US FDA that it will discontinue commercialization of its hepatitis C virus (HCV) drug Victrelis (boceprevir) in the United States by the end of 2015. The anti-viral will continue to be sold in other international markets where it is still an important treatment option, but Victrelis will be discontinued in the US 'due to advances in treatment practices and the consequent reduction in demand for Victrelis'.

Andalusia Awards EUR 442,000 Pharmaceuticals Supply Tender to Merck

Servicio Andaluz de Salud has hired Merck for the supply of exclusive medicaments. The final value of the deal is EUR 442,000 (USD 512,000), excluding VAT. The contract term has not been specified in the contract award notice with document number 21061-2015. The above stated supplies are intended for the healthcare logistics platform in the Granada province. The tender was awarded without the prior publication of a contract notice due to technical reasons. The award procedures took place on November 15, 2014.

Eli Lilly and Company and Merck Enter Collaboration Agreement

Merck and Eli Lilly and Company announced an oncology clinical trial collaboration to evaluate the safety, tolerability and efficacy of Keytruda (pembrolizumab), Merck's anti-PD-1 therapy, in combination with Lilly compounds in multiple clinical trials. Merck will conduct a phase II study examining the combination of pembrolizumab with pemetrexed in first-line non-squamous, non-small cell lung cancer (NSCLC). This study is currently enrolling. Lilly will conduct a multiple-arm Phase I/II study examining the combination of ramucirumab with pembrolizumab in multiple tumours. This study is anticipated to begin in 2015. Lilly will conduct a phase I/II study examining the combination of necitumumab with pembrolizumab in NSCLC. This study is anticipated to begin in 2015.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
6MK:GR €54.18 EUR -0.271

6MK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bayer AG €129.56 EUR +2.08
Gilead Sciences Inc $104.18 USD +1.73
GlaxoSmithKline PLC 1,493 GBp -4.00
Roche Holding AG SFr.252.70 CHF +1.00
Sanofi €82.26 EUR +0.27
View Industry Companies

Industry Analysis


Industry Average

Valuation 6MK Industry Range
Price/Earnings 33.6x
Price/Sales 4.1x
Price/Book 3.9x
Price/Cash Flow 32.5x
TEV/Sales 3.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MERCK & CO. INC., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at